Toshiba Announced FDA approval of Auto-IMT Ultrasound Software

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Endo Announces Peyronie’s Disease Presentation at...

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today...

Leadership at NHS Hospitals in Leeds...

A watchdog has gone on to say that the...

Developing Dr. CaBot, A Medical Education...

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for...

The medicines regulator of the UK has announced plans...

Feb 16th 2011 :- For physicians, the ability to streamline exams for determining a patient’s risk for cardiovascular disease is important in determining the patient’s clinical pathway. To enhance diagnostic efficiency, Toshiba America Medical Systems, Inc. has introduced Auto-IMTTM, an ultrasound software tool that can measure the thickness of the intima-media layers of the carotid artery, for evaluating an asymptomatic patient’s risk of developing cardiovascular disease. Toshiba has recently received FDA clearance for Auto-IMT, and it is now available on the AplioTM XG, Aplio MX and XarioTM XG ultrasound systems.

David Parlato, director, Clinical Operations, Midwest Ultrasound commented, Auto-IMT has helped us reduce the time it takes to evaluate carotid artery wall thickness from 45 minutes to less than 10 minutes, allowing us to evaluate more patients in less time.

Tomo Hasegawa, director, Ultrasound Business Unit, Toshiba said, Measuring IMT at a faster pace helps identify high-risk patients before a cardiac episode occurs, which we believe leads to better patient outcomes.

Latest stories

Related stories

Developing Dr. CaBot, A Medical Education Tool That Reasons

Harvard Medical School researchers are developing Dr. CaBot as...

UK & U.S. Regulators Partner for Medtech Regulatory Reforms

The medicines regulator of the UK has announced plans...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »